G1 Basic

UltraPlex Proteomics Platform

The Nanomation™ G1 Basic can process up to 48 samples in a single run, facilitating large-scale proteomics cohort studies.

It reduces the sample pretreatment time from 2-3 days to just 8-9 hours, allowing customers to expedite their projects efficiently.

Features

Automated

Built-in standard workflows, one-click start

Open

Ability to create customized workflows

High throughput

Up to 48 samples

per run

The Nanomation™ G1 Basic is an automated workstation developed for proteomics research and protein enrichment.

The Nanomation™ G1, along with its reagents and consumables, provides researchers with a complete proteomics research workflow, assisting researchers in conducting unbiased, in-depth, and large-scale proteomics studies. The unique nanoparticles are capable of unbiasedly capturing the proteome in the samples, and they are compatible with most mass spectrometry platforms.

Components

8-channel pipettor

used for liquid transfer operations during the experiment.

Gripper

used to transfer plate among slots and modules.

Heater shaker

used for the heating and mixing samples and reagents.

Magnetic module

used for the collection of nanoparticles.

Extend ports

Backup ports for the communication of control pad and instrument.

Applications

Discovery of Protein Biomarkers

Detection of diseases through bodily fluids such as blood, is increasingly becoming the mainstream approach for clinical screening and diagnosis. Currently, there are already 100-200 plasma proteins approved by the FDA as disease biomarkers.

Clinical Trial Patient Screening & Stratification

Large-scale plasma proteomics discovery aids in more accurate patient screening, understanding patient characteristics, and identifying additional biomarkers. This enhances the accuracy and reliability of clinical trials, providing more guidance and information for clinical practice.

New Target
Discovery

Proteins are key to cellular functions and reflect gene expression levels. Recent advances in mass spectrometry-based proteomics have opened new possibilities for studying disease mechanisms and discovering therapeutic targets.

Drug Efficacy Prediction and Assessment

Proteomics is widely employed in clinical drug efficacy assessment. Through proteomic techniques, the impact of drugs on proteins within the human body can be thoroughly studied, enabling the evaluation of drug efficacy and side effects.

Nanomics Biotech